Macrophage CREBZF Orchestrates Inflammatory Response to Potentiate Insulin Resistance and Type 2 Diabetes
Liu Y., Su W., Liu Z., Hu Z., Shen J., Zheng Z.
Animal Study on Type 2 Diabetes, Chronic Inflammation, published in Adv Sci (Weinh) (2024) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Adv Sci (Weinh) (2024)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 38286660
- PMCID
- PMC10987118
- DOI
- 10.1002/advs.202306685
- Citations
- 14
Abstract (original English)
Chronic adipose tissue inflammation accompanied by macrophage accumulation and activation is implicated in the pathogenesis of insulin resistance and type 2 diabetes in humans. The transcriptional coregulator CREBZF is a key factor in hepatic metabolism, yet its role in modulating adipose tissue inflammation and type 2 diabetes remains elusive. The present study demonstrates that overnutrition-induced CREBZF links adipose tissue macrophage (ATM) proinflammatory activation to insulin resistance. CREBZF deficiency in macrophages, not in neutrophils, attenuates macrophage infiltration in adipose, proinflammatory activation, and hyperglycemia in diet-induced insulin-resistant mice. The coculture assays show that macrophage CREBZF deficiency improves insulin sensitivity in primary adipocytes and adipose tissue. Mechanistically, CREBZF competitively inhibits the binding of IκBα to p65, resulting in enhanced NF-κB activity. In addition, bromocriptine is identified as a small molecule inhibitor of CREBZF in macrophages, which suppresses the proinflammatory phenotype and improves metabolic dysfunction. Furthermore, CREBZF is highly expressed in ATM of obese humans and mice, which is positively correlated with proinflammatory genes and insulin resistance in humans. This study identifies a previously unknown role of CREBZF coupling ATM activation to systemic insulin resistance and type 2
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
The Influence of GLP-1 Agonists on Human Mesenchymal Stem Cells: A Systematic Review
Systematic Review on Type 2 Diabetes, published in Stem Cell Rev Rep (2026) — summary generated from the PubMed abstract.
- 2026
Stem Cell Rev Rep2 citations - Level ASystematic ReviewEurope PMC
Dedifferentiation of Mature Adipocytes and Their Future Potential for Regenerative Medicine Applications
Systematic Review on Type 2 Diabetes, Chronic Wound, published in Biomedicines (2026) — summary generated from the PubMed abstract.
- 2026
Biomedicines - Level ASystematic ReviewEurope PMC
Consolidating Clinical Insights and Uncovering Novel Regulatory Mechanisms of Exosomal MicroRNAs in Obesity and Metabolic Dysfunction Associated Steatotic Liver Disease: A Systematic Review and Bioinformatics Analysis
Systematic Review on Type 2 Diabetes, Chronic Inflammation, published in Food Sci Nutr (2026) — summary generated from the PubMed abstract.
- 2026
Food Sci Nutr - Level AMeta-analysisEurope PMC
Autologous and allogeneic mesenchymal stem cell-based therapies for diabetes mellitus: A systematic review and meta-analysis
Meta-analysis on Type 2 Diabetes, Immune Modulation, published in World J Stem Cells (2025) — summary generated from the PubMed abstract.
- 2025
World J Stem Cells1 citations - Level ASystematic ReviewPubMed
Systematic Review: Exosomes as Molecular Messengers in the Development of Obesity-Related Complications in Children.
Systematic Review on Type 2 Diabetes, published in Curr Issues Mol Biol (2025) — summary generated from the PubMed abstract.
- 2025
Curr Issues Mol Biol - Level AMeta-analysisEurope PMC
Thiamine as a putative natural modulator of PPARγ: exploring a nutrient-based approach for type 2 diabetes
Meta-analysis on Type 2 Diabetes, published in Front Pharmacol (2025) — summary generated from the PubMed abstract.
- 2025
Front Pharmacol